An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

Summary

To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving treatment for life- or sight-threatening cytomegalovirus infections.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications